RXRX:NASDAQRecursion Pharmaceuticals, Inc. Analysis
Data as of 2026-08-09 - not real-time
$3.22
Latest Price
9/10Risk
Risk Level: High
Executive Summary
The moving-average structure behind Recursion Pharmaceuticals, Inc. is bearish at $3.22, with short-term averages lagging the long-term ones. It has lost 3.6% over the past 30 days. With RSI at 50.9 the momentum picture is neutral, alongside a bullish MACD signal. The recent range runs from support at $2.84 up to resistance at $3.54.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 125.2% above where the shares trade now. Revenue is contracting at 60.1%.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 60.9%, a beta of 2.88 and a maximum drawdown of 58.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
The horizons line up on hold — conviction 1 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 125.2% above where the shares trade now. Revenue is contracting at 60.1%.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 60.9%, a beta of 2.88 and a maximum drawdown of 58.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
The horizons line up on hold — conviction 1 out of 10.
Top Market Events
Recursion Pharmaceuticals RXRX reported a loss of 25 cents per share in the second quarter of 2026, wider than the...Recursion Pharmaceuticals, Inc. NASDAQ:RXRX is one of the Best Penny Stocks to Invest In According to Billionaires....Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 3.83
- MACD momentum is positive
Medium Term
1–3 yearsNeutral
Model confidence: 2/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 3.83
- Analyst targets imply +125.2% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- Analyst targets imply +125.2% versus the current price
- Negative return on equity of -56.6%
- Revenue contracting at -60.1%
Key Metrics & Analysis
Financial Health
Revenue Growth-60.10%
P/E Ratio-3.5
ROE-56.58%
ROA-27.33%
Debt/Equity7.28
P/B Ratio1.9
Op. Cash Flow$-350480992
Free Cash Flow$-219493744
Industry P/E29.5
Technical Analysis
TrendBearish
RSI50.9
Support$2.84
Resistance$3.54
MA 20$3.10
MA 50$3.32
MA 200$3.83
MACDBullish
VolumeDecreasing
Fear & Greed Index94.82
Valuation
Target Price$7.25
Upside/Downside125.16%
GradeFair
TypeBlend
Risk Assessment
Beta2.88
Volatility60.95%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.